Zhejiang Hisoar Pharmaceutical 과거 수익 실적
과거 기준 확인 0/6
Zhejiang Hisoar Pharmaceutical's earnings have been declining at an average annual rate of -72.6%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 5.4% per year.
주요 정보
-72.6%
수익 성장률
-74.1%
EPS 성장률
Pharmaceuticals 산업 성장 | 10.9% |
매출 성장률 | -5.4% |
자기자본 수익률 | -6.8% |
순이익 | -19.0% |
최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Price Is Out Of Tune With Revenues
Sep 27Does Zhejiang Hisoar Pharmaceutical (SZSE:002099) Have A Healthy Balance Sheet?
Aug 30Zhejiang Hisoar Pharmaceutical (SZSE:002099) Has Debt But No Earnings; Should You Worry?
May 27Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Shares Climb 28% But Its Business Is Yet to Catch Up
Mar 03수익 및 비용 분석
Zhejiang Hisoar Pharmaceutical 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 24 | 1,940 | -369 | 335 | 120 |
30 Jun 24 | 2,014 | -401 | 343 | 117 |
31 Mar 24 | 2,066 | -430 | 337 | 115 |
31 Dec 23 | 2,172 | -420 | 332 | 116 |
30 Sep 23 | 2,310 | -158 | 301 | 129 |
30 Jun 23 | 2,433 | -64 | 342 | 136 |
31 Mar 23 | 2,534 | 43 | 383 | 141 |
01 Jan 23 | 2,704 | 88 | 425 | 145 |
30 Sep 22 | 2,765 | 226 | 466 | 149 |
30 Jun 22 | 2,764 | 206 | 518 | 154 |
31 Mar 22 | 2,647 | 125 | 522 | 159 |
01 Jan 22 | 2,485 | 95 | 574 | 165 |
30 Sep 21 | 2,310 | 34 | 558 | 166 |
30 Jun 21 | 2,352 | 115 | 527 | 153 |
31 Mar 21 | 2,538 | 272 | 484 | 146 |
31 Dec 20 | 2,471 | 320 | 465 | 132 |
30 Sep 20 | 2,518 | 443 | 444 | 123 |
30 Jun 20 | 2,517 | 541 | 409 | 123 |
31 Mar 20 | 2,685 | 673 | 408 | 118 |
31 Dec 19 | 2,941 | 771 | 394 | 123 |
30 Sep 19 | 3,030 | 812 | 407 | 122 |
30 Jun 19 | 3,085 | 825 | 408 | 119 |
31 Mar 19 | 2,940 | 763 | 416 | 117 |
31 Dec 18 | 2,719 | 605 | 371 | 111 |
30 Sep 18 | 2,651 | 540 | 368 | 118 |
30 Jun 18 | 2,447 | 375 | 304 | 167 |
31 Mar 18 | 2,335 | 271 | 297 | 139 |
31 Dec 17 | 2,309 | 342 | 323 | 114 |
30 Sep 17 | 2,251 | 76 | 388 | 77 |
30 Jun 17 | 2,376 | 165 | 477 | 0 |
31 Mar 17 | 2,376 | 208 | 511 | 0 |
31 Dec 16 | 2,434 | 225 | 508 | 0 |
30 Sep 16 | 2,493 | 500 | 469 | 0 |
30 Jun 16 | 2,475 | 489 | 470 | 0 |
31 Mar 16 | 2,486 | 489 | 467 | 0 |
31 Dec 15 | 2,464 | 517 | 468 | 0 |
30 Sep 15 | 2,355 | 496 | 464 | 0 |
30 Jun 15 | 2,036 | 378 | 379 | 0 |
31 Mar 15 | 1,669 | 211 | 310 | 0 |
31 Dec 14 | 1,319 | 54 | 259 | 0 |
30 Sep 14 | 1,158 | -51 | 220 | 0 |
30 Jun 14 | 1,126 | -77 | 224 | 0 |
31 Mar 14 | 1,135 | -82 | 223 | 0 |
31 Dec 13 | 1,161 | -82 | 211 | 0 |
양질의 수익: 002099 is currently unprofitable.
이익 마진 증가: 002099 is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 002099 is unprofitable, and losses have increased over the past 5 years at a rate of 72.6% per year.
성장 가속화: Unable to compare 002099's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: 002099 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
자기자본 수익률
높은 ROE: 002099 has a negative Return on Equity (-6.81%), as it is currently unprofitable.